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Abstract
Background: Optical imaging is an attractive non-invasive way to evaluate the expression of a
transferred DNA, mainly thanks to its lower cost and ease of realization. In this study optical
imaging was evaluated for monitoring and quantification of the mouse knee joint and tibial cranial
muscle electrotransfer of a luciferase encoding plasmid. Optical imaging was applied to study the
kinetics of luciferase expression in both tissues.
Results: The substrate of luciferase (luciferin) was injected either intraperitonealy (i.p.) or in situ
into the muscle or the knee joint. Luminescence resulting from the luciferase-luciferin reaction was
measured in vivo with a cooled CCD camera and/or in vitro on tissue lysate. Maximal luminescence
of the knee joint and muscle after i.p. (2.5 mg) or local injection of luciferin (50 µg in the knee joint,
100 µg in the muscle) were highly correlated. With the local injection procedure adopted, in vivo
and in vitro luminescences measured on the same muscles significantly correlated. Luminescence
measurements were reproducible and the signal level was proportional to the amount of plasmid
injected. In vivo luciferase activity in the electrotransfered knee joint was detected for two weeks.
Intramuscular electrotransfer of 0.3 or 3 µg of plasmid led to stable luciferase expression for 62
days, whereas injecting 30 µg of plasmid resulted in a drop of luminescence three weeks after
electrotransfer. These decreases were partially associated with the development of an immune
response.
Conclusion: A particular advantage of the i.p. injection of substrate is a widespread distribution at
luciferase production sites. We have also highlighted advantages of local injection as a more
sensitive detection method with reduced substrate consumption. Besides, this route of injection is
relatively free of uncontrolled parameters, such as diffusion to the target organ, crossing of
biological barriers and evidencing variations in local enzymatic kinetics, probably related to the
reaction medium in the targeted organ. Optical imaging was shown to be a sensitive and relevant
technique to quantify variations of luciferase activity in vivo. Further evaluation of the effective
amount of luciferase in a given tissue by in vivo optical imaging relies on conditions of the enzymatic
reaction and light absorption and presently requires in vitro calibration for each targeted organ.
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Background
Methods of gene transfer to tissues are still to be opti-
mized. Successful human gene therapy requires effective
gene delivery and long term expression of the transgene.
Among gene transfer methods, plasmid electrotransfer is a
physical method for in vivo non viral gene delivery. The
main target organs of this method are the skeletal muscle,
which allows systemic secretion of the therapeutic pro-
tein, some tumors, as well as the skin, mainly for vaccina-
tion applications [1]. The field of applications of
electrotransfer is still expanding, with the use of this
method in other organs, such as cornea [2], tendon [3],
liver [4], bladder [5], brain [6]. However, most of these
studies focused on the establishment of transfer tech-
niques.
To assess the feasibility, efficacy and patterns of gene
transfer methods, there is a real need for simple and pre-
cise methods of evaluation. In that context, non-invasive
evaluation of transfection is of great interest. This type of
method allows to follow simultaneously the distribution
and expression level of transferred DNA at different times
reducing the number of animals used and improving sta-
tistical analysis, with each animal acting as its own con-
trol. Among different methods [7,8], optical imaging is
particularly attractive because of its lower cost and easi-
ness of realization. However, more sophisticated methods
of quantitative tomography have been proposed for fluo-
rescence [9] and are emerging for luminescence [10].
Imaging is made with a CCD (Charged Coupled Device)
camera, which relies on the conversion of photons that
strike a CCD pixel into spatially defined electric charges.
Various reporter genes, encoding fluorescent proteins of
different emission wavelength or bioluminescent pro-
teins, are available for this method. The use of luciferase
as a reporter gene requires injection of an exogenous sub-
strate but there is no need of illumination which can per-
turb physiology in light sensitive tissues [11]. Luciferases
are presently more sensitive than fluorescent reporters,
thanks to a high quantum yield associated to a very low
background level of luminescence [12,13]. Sensitivity is
currently increasing with further development of brighter
forms of luciferase [14] and red shifted mutants [15].
Moreover, luciferases have a rapid turnover (t1/2 of 3
hours) which allows real-time measurements of the pro-
tein production in vivo [16].
Luciferases are currently used as reporters of many biolog-
ical functions [13,17]. It can be a useful tool to monitor
protein-protein interactions by BRET (Bioluminescence
Resonance Energy Transfer) or by LCI (Luminescence
Complementation Imaging) [17]. The luciferase gene can
also be used as a tracer to study tumor growth and metas-
tasis [18,19], to follow labelled infectious bacteria or
viruses [20]. Tracing of in vivo transgene expression after
transfection of different tissues by DNA encoding luci-
ferase is applicable [21,22]. Luciferase expression has
been a useful tool to monitor the transcriptional activa-
tion of a gene [23,24], and transgenic mice can allow the
evaluation of the efficacy of therapeutic interventions
[25].
Consequently, if the method is to be largely used in ani-
mal research, problems of quantification remain to be
studied and discussed. In vivo, to our knowledge only one
study was presently devoted to quantification of gene
transfer by optical imaging of luminescence [22]; in this
work, the transfection was performed in the muscle with
a luciferase-encoding AAV vector, following an i.p. injec-
tion of the substrate luciferin. Thus, it seemed useful to
further analyze if the quantification of gene transfer by
optical imaging was feasible in a simple and reliable way,
possibly in several organs simultaneously, and whether a
local substrate injection could be a good alternative. Our
experimental model was the electrotransfer of the tibial
cranial muscle [26,27] and/or the knee joint [28,29] with
a plasmid encoding luciferase.
In this study, i.p. and local route of administration of luci-
ferin were compared. As validated, the local injection
method led to more sensitive luminescence detection
than the i.p. substrate injection. Quantification of the in
vivo luminescence thus obtained, was highly correlated to
the in vitro measurements on the same organ. Reproduci-
ble measurements were obtained with the CCD camera
device. This non-invasive approach to quantify gene
expression in various organs was then applied to kinetic
studies in the muscle and knee.
Results
Comparison of different routes of administration of 
luciferin substrate
The enzymatic reaction to visualize luciferase activity is
generally obtained following intraperitoneal luciferin
injection. This route of injection should allow the sub-
strate to reach any location where luciferase is produced
[21]. However the substrate local availability depends on
some features such as blood perfusion and the nature of
physiological barriers to cross (endothelium, extracellular
matrix, epithelium ...). I.p. luciferin accessibility was stud-
ied in two different types of compartment: skeletal muscle
and joint. We chose these two tissues in particular, since
they are both interesting targets for electrotransfer, and
they are very different in size, cellular type and vascula-
ture.
By electrotransfering a luciferase-encoding plasmid into
the right knee and the left muscle of the same mouse it
was possible to observe simultaneously the luminescence
in both tissues after i.p. injection of luciferin (Figure 1A).BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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A Luminescence of tibial cranial muscle and knee joint area after electrotransfer of a luciferase-encoding plasmid and i.p. injec- tion of luciferin Figure 1
A Luminescence of tibial cranial muscle and knee joint area after electrotransfer of a luciferase-encoding plas-
mid and i.p. injection of luciferin. Observation was done 26 minutes after i.p. injection of luciferin (2.5 mg/250 µl) and 7 
days after electrotransfer of 3 µg and 60 µg of luciferase encoding plasmid (pC1-luc) into the tibial cranial muscle (on the left) 
and the knee joint (on the right) respectively. Levels of luminescence are represented in false colours according to a scale from 
400 to 1500 (whole scale 65000). 1B and 1C Fluorescence of knee joint after injection of fluorescent albumin. Skin of 
the leg was removed. Fluorescence was induced with λex = 540 +/- 20 nm and observation was done at λem > 630 nm. Panel 
B: At these wavelengths, without injecting fluorochrome, it was possible to see bones by transparency. Panel C Just after injec-
tion, labelled albumin is concentrated within patella of the knee joint and some diffusion of fluorescence within the joint can be 
observed. Levels of fluorescence are represented in false colors.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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We controlled the procedure of injection into the knee
joint using fluorescent albumin. After removal of the skin,
it was possible to see better the fluorescence localization
relative to bones, knee joint and muscle. Position of the
knee can be seen in figure 1B. After intra-articular injec-
tion of fluorescent albumin a bright spot of fluorescence
was observed at the level of the patella (Fig 1C); some dif-
fusion of albumin was visible in the whole joint and also
partly outside. From the position of the knee joint in the
hind leg, it appeared that the transfection area, as shown
by luminescence spot in figure 1A would be within the
joint, but transfection of adjacent tissues could not be
excluded. In agreement with previous results [21,22] a
plateau level of luminescence was reached after about 20
to 30 min for the muscle as for the knee joint area (figure
2A). However the time required to reach the plateau level
of luminescence in muscle or knee area was variable
between different experiments and the amount of luci-
ferin to inject was relatively high (2.5 mg). We thus tested
if local injection of a lower amount of luciferin was a valid
alternative. In addition such a procedure would more
selectively evidence the knee joint transfection. We
injected 100 µg/40 µl into the muscle and 50 µg/10 µl
into the knee joint. Under these conditions, the substrate
Kinetics of luminescence of tibial cranial muscle and knee joint after electrotransfer of a luciferase encoding-plasmid and either  i.p. or local injection of luciferin Figure 2
Kinetics of luminescence of tibial cranial muscle and knee joint after electrotransfer of a luciferase encoding-
plasmid and either i.p. or local injection of luciferin. 3 and 60 µg of a plasmid encoding luciferase were electrotransfered 
into the left tibial cranial muscle and right knee joint respectively. Luminescence measurements were done 7 days after electro-
transfer. Values are mean +/- SEM of the integrated values of luminescence in region of interest (ROI) of the knee joint or of 
the tibial cranial muscle. For all experiments, the first measurement was performed 2 minutes after luciferin injection. Panel A: 
i.p. luciferin injection (2.5 mg/250 µl), n = 5 Panel B: local luciferin injection into the muscle (100 µg/40 µl) and into the knee 
joint (50 µg/10 µl), n= 5/organ. Luminescence decreased with time in the muscle (t1/2 = 3.3 minutes), and in the knee joint (t1/
2= 16.5 minutes).BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
Page 5 of 15
(page number not for citation purposes)
was in large excess relative to the expected amount of luci-
ferase produced that should be of a few ng (in the muscle)
[30]. Besides, injecting 3 to 4 times more substrate into
joint or muscle did neither modify the level of lumines-
cence nor the decrease profile, confirming that the sub-
strate was actually in excess and thus was not a limiting
factor in the targeted organ (data not shown). A fast lumi-
nescence decrease occurred as soon as the first measure-
ments (2 minutes after local substrate injection). The t1/2
of the decrease was 16.5 min for knee joint and 3.3 min
for skeletal muscle (Figure 2B). In addition, in both tis-
sues a subsequent injection of the same amount of luci-
ferin after one hour delay induced similar luminescence
production (data not shown).
After electrotransfer of 3 and 60 µg of plasmid encoding
luciferase into muscle and knee joint of the same mouse,
respectively, the luminescence was about 4 times higher
after local injection of 100 µg luciferin into muscle and 50
µg into knee than after i.p. injection of 2.5 mg luciferin
(Table 1 – experiment 1). This 4-fold increase by the local
substrate administration was confirmed by intramuscular
electrotransfer of a higher plasmid dose (30 µg) as shown
in table 1 – experiment 2. Nevertheless, maximal lumines-
cence values obtained after local luciferin injection (100
µg/40 µl) were significantly correlated to those after i.p.
injection (2.5 mg/250 µl).
We have also tested whether the sensitivity of the i.p.
injection method could be improved when compared to
the one of the muscle local procedure. For this purpose,
we used an i.p. injection dose of 6 mg of substrate instead
of 2.5 mg. The luminescence signal detected was
increased, but remained below the one obtained by local
injection. By i.p. procedure, the substrate is thus not in
sufficient excess, even by injecting 6 mg of substrate, rela-
tive to enzyme concentration in the targeted tissue (Table
2).
These experiments thus highlighted the relevance of local
injection with an excess of luciferin substrate, which
allows luminescence detection highly correlated with i.p.
injection. The major drawback of this method is the rapid
decrease of the signal, which requires performing all
measurements at the same and precisely determined time
after luciferin injection. For all the following experiments,
we used this local injection protocol.
Comparison between in vivo and in vitro measurements of 
luciferase activity
One of the purposes of this study was to determine
whether the levels of luminescence obtained from in vivo
mouse muscle with a CCD camera were quantitatively
reflective of the ones detected in vitro after lysis of each
muscle and classical biochemical measurement with a
Table 1: Comparison between local and i.p. injection of luciferin to induce luminescence after electrotransfer of a plasmid encoding 
luciferase into the knee joint or tibial cranial muscle
Experiment 1 (n = 5) Experiment 2 (n = 8)
Knee 60 µg Muscle 3 µg Muscle 30 µg
Local i.p. Local i.p. Local i.p.
Luminescence Millions units/min 4.37 ± 1.40 1.18 ± 0.25 3.08 ± 1.81 0.74 ± 0.38 20.41 ± 5.62 4.86 ± 1.20
Ratio local/i.p. 3.46 ± 0.76 3.55 ± 0.96 3.91 ± 0.38
Correlation r2 = 0.817 r2 = 0.929 r2 = 0.980
local/i.p. p = 0.0351 p = 0.0082 p < 0.0001
Values are mean ± SEM of the integrated values of luminescence in ROI of the muscle or of the knee. In the first experiment, 60 and 3 µg of 
luciferase-encoding plasmid were electrotransferred into one knee joint and one tibial cranial muscle respectively. Luminescence was measured 
with the CCD camera 3 days after electrotransfer. In the second experiment, 30 µg of plasmid were electrotransferred into both tibial cranial 
muscles and luminescence was measured 7 days later. For all the experiments, luciferin was injected either locally (50 µg in the knee, 100 µg in the 
muscle) or i.p. (2.5 mg).
Table 2: Comparison of luminescence of tibial cranial muscles after electrotransfer of a luciferase-encoding plasmid and injection of 
luciferin i.p. (2.5 mg or 6 mg) or locally (0.1 mg)
Luciferin administration i.p. local
2.5 mg 6 mg 0.1 mg
Luminescence 105 units/min 2.05 ± 0.32 7.06 ± 2.79 18.42 ± 2.68
Values are mean ± SEM (n = 6 to 12) of the integrated values of luminescence in ROI of the tibial cranial muscle 3 days after electrotransfer of 3 µg 
of pC1 luc plasmid as measured in vivo after luciferin injection i.p. (2.5 mg/250 µl, n = 6 or 6 mg/250 µl, n = 6) or locally (0.1 mg/40 µl n = 12). Local 
injection of luciferin was performed 2 hours or more after the i.p. injection. Background luminescence was subtracted from the luminescence 
measured.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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luminometer. This part of the study was made only with
muscle tissue, for which the in vitro biochemical assay has
been optimized. Besides, measurements on the mice knee
joint would be difficult both for sampling and lysis rea-
sons. Indeed we could not accurately determine which
cells were transfected in the joint, as we found expression
both in the patella area but also in the whole joint region
(delimited by the heads of the femur and the tibia) (Data
not shown). Moreover lysis of the articular tissues would
require use of collagenase which may not be compatible
with the biochemical assay buffer.
To determine the conversion factor between the lumi-
nometer used for in vitro assays and the CCD camera used
for in vivo imaging, we quantified the luminescence pro-
duced by different concentrations of luciferase in a 96 well
plate in the presence of an excess of luciferin with both
systems. Such a calibration was unfortunately not possi-
ble directly in vivo in mouse tissues (see Material and
Methods). A good linear correlation was found between
luminescence levels and luciferase amounts at different
time after luciferin addition with the camera and with the
luminometer, two min after substrate addition (r2 = 0.994
and r2 = 0.988 respectively, p < 0.001). During the first 5
minutes after luciferin addition the luminescence levels
measured with the luminometer or the cooled CCD cam-
era with the setting chosen (see Material and Methods)
were very similar. Thus comparisons between measure-
ments with both systems were made without any modifi-
cations of the values.
We determined the sensitivity of both measurement sys-
tems to detect luminescence of the luciferase-luciferin
reaction in the optimized conditions in vitro. With the
luminometer the lowest clearly detectable luminescence
corresponded to a luciferase amount of about 0.01 ng (10
µl of a 1 ng/ml solution). With the CCD camera it corre-
sponded to an amount of 0.05 ng (10 µl of a 5 ng/ml solu-
tion) due to a higher background.
Three doses of plasmid pC1luc (0.3, 3 and 30 µg) were
then used to establish the comparison between in vivo and
in vitro measurements. This comparison was made 8 days
after i.m electrotransfer, when a maximum expression
level was reached.
Figure 3 shows the luminescence levels as measured in vivo
with the CCD camera and in vitro on lysates of the same
muscle using the luminometer on white plates. The mean
level of luminescence was higher in vitro than in vivo by 3
orders of magnitude. In spite of this difference in vitro and
in vivo values of luminescence were significantly corre-
lated (r2 = 0.796 p < 0.0001; Number of paired values =
28).
Accordingly, dose dependence between luciferase activity
and injected plasmid doses was both observed in vitro and
in vivo (figures 3, 4, 5).
Figure 4 shows that luminescence resulting from the reac-
tion between luciferase and luciferin in the muscle can be
detected by optical imaging as soon as 6 hours after elec-
trotransfer of 0.3 µg of pCMV-luc+. By comparing in vivo
and in vitro measurements of muscle luminescence and
using in vitro calibration curves with recombinant luci-
ferase, we could estimate the amount of luciferase in these
muscles which was of about 3 ng (see appendix). The
CCD device thus appeared as a sensible tool to quantify
luciferase expression in a living organism.
Reproducibility of in vivo luminescence measurements in 
the muscle tissue
It is known that gene expression following intramuscular
electrotransfer reaches a stable maximum value one week
after the injection. At this point, individual values should
be consistently reproducible. We used this well known
property of the electrotransfer method to validate the
reproducibility of measurements with the CCD device.
Mean levels of in vivo luminescence at days 7 and 8 after
electrotransfer of 0.3, 3 or 30 µg of the pC1-luc plasmid
were comparable as expected (Figure 5) and were signifi-
cantly correlated (inset) (r2 = 0.92 p < 0.0001). Significant
correlations between values at days 7 and 8 were also
observed by analyzing separately the three groups of val-
ues corresponding to the three amounts of plasmid elec-
trotransfered (0.3 µg, r2 = 0.89, p < 0.0001; 3 µg, r2 = 0.59,
p = 0.026; 30 µg, r2 = 0.77, p = 0.0008).
Kinetic of luciferase expression in the electrotransfered 
knee joint and skeletal muscle
From the above results it appears that in vivo luciferase
quantification is a reliable methodology. We thus used
this non-invasive method to study kinetics profile of luci-
ferase activity in knee joint and skeletal muscle.
The expression of luciferase in the knee joint area was fol-
lowed for two weeks after electrotransfer of 60 µg of pC1-
luc or the same dose of a control plasmid with no encod-
ing sequences. A maximum value of luminescence was
reached between 3 and 6 days after electrotransfer. Expres-
sion of luciferase gradually decreased thereafter and
returned close to the control level 13 days after the electro-
transfer (Figure 6A).
In skeletal muscle, luciferase expression was stable for at
least two months following the electrotransfer of either
0.3 µg plasmid (Figure 6B) or of 3 µg (data not shown).
By contrast, a decrease of luminescence at day 19 for the
high dose of 30 µg plasmid, was observed. At day 62 the
luminescence for muscle electrotransfered with 30 µgBMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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plasmid was comparable to that of muscle electrotrans-
fered with 0.3 µg plasmid and was significantly decreased
relative to that at 19 days.
Thirteen days after electrotransfer of knee with 60 µg plas-
mid encoding luciferase, the presence of antibodies
against luciferase was detected in the serum of treated
mice (65 ± 17 µg/ml). No antibodies were detected in
serum of mice until 61 days after electrotransfer of tibial
cranial muscles with 0.3 µg of plasmid. By contrast, when
the amount of plasmid injected in the muscles was 30 µg,
antibodies were clearly detected in serum at an increasing
level between days 19 to 61 after electrotransfer (inset Fig-
ure 6B).
Discussion
The use of luciferase as a reporter gene is a powerful tool
for in vivo optical imaging of the transfection of various
organs [21]. Until now, luminescence has been mainly
induced by substrate (luciferin) injected intraperitoneally
[21,22]. We have shown that this approach allows simul-
taneous visualization of the transfection of tibial cranial
Comparison between the in vivo and in vitro measurements of luciferase activity of tibial cranial muscle after electrotransfer  with a luciferase-encoding plasmid Figure 3
Comparison between the in vivo and in vitro measurements of luciferase activity of tibial cranial muscle after 
electrotransfer with a luciferase-encoding plasmid. Values are mean +/- SEM (n = 10) of the integrated values of lumi-
nescence in ROI of the tibial cranial muscle 8 days after electrotransfer of 0.3, 3 or 30 µg of pC1 luc plasmid as measured in vivo 
(white columns) and in vitro 3 hours later or more (grey columns) on the same muscles. Individual values are represented by 
black triangles and the lines link values measured in vivo and in vitro for the same muscles. In vivo background luminescence was 
subtracted from the luminescence measured. In vitro, background luminescence was negligible. Dose effect: – in vitro **** p < 
0.0001 between electrotransfer with 0.3 and 3 µg of plasmid ** p < 0.01 between 3 and 30 µg of plasmid – in vivo $$ p < 0.01 
between electrotransfer with 0.3 and 3 µg of plasmid.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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muscle and knee joint area in the same mouse. This indi-
cates that the substrate can reach even a small and less per-
fused compartment such as the knee joint. Such a
detection method is of particular interest for the knee,
since quantitative in vitro measurement of luciferase activ-
ity in this tissue is difficult and has been reported only for
bigger animals such as the rat [28,29]. Following luciferin
i.p. injection, curves of luminescence versus time had a
similar pattern in both muscle and joint. However, the
time to reach maximum level of expression was variable
from one experiment to the other, and the amount of luci-
ferin used was relatively high. Moreover, by using a higher
dose of substrate (6 mg), we demonstrated that the maxi-
mal level of luminescence is not reached with the com-
monly used dose of 2.5 mg substrate. In addition,
selective transfection of the knee joint is difficult and
sometimes neighboring tissues can also be transfected. We
therefore tested if the local injection of lower amounts of
luciferin could be used alternatively, the other advantage
being a more selective estimation of transfection for the
knee joint.
Comparison between i.p. and local luciferin administration
By local injection of the substrate, a maximal value of
luminescence was detected in both muscle and joint as
soon as the first CCD camera observation. Luminescence
then decreased rapidly in the muscle and somewhat
slower in the knee joint. Most importantly, luciferin local
Sensitivity of in vivo luminescence measurements and dose effect Figure 4
Sensitivity of in vivo luminescence measurements and dose effect. Values are mean +/- SEM of the integrated values of 
luminescence in ROI of the tibial cranial muscle 6 h (n = 6 to 10), 1 day and 8 days (n = 10 to 20) after electrotransfer of 0.3 µg 
(white columns), 3 µg (clear grey columns) and 30 µg (dark grey columns) of pCMV-luc+ into the tibial cranial muscle. For all 
points, background luminescence was subtracted. Statistical significance of the differences **** p < 0.0001, ** p < 0.01, * p < 
0.05.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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injection led to a four fold luminescence increase over 2.5
mg luciferin i.p. injection. Additionally, i.p. injection of a
higher amount of 6 mg luciferin still did not allow to
reach the luminescence level obtained after local injection
of 100 µg luciferin. Maximal luminescence levels
obtained after i.p. (2.5 mg) or local (0.1 mg) injection of
luciferin were highly correlated in both knee and muscle,
even when different amounts of plasmid were adminis-
trated in the muscle. This indicates that both procedures
of luciferin injection can be used for monitoring varia-
tions of luciferase activity in vivo independently of the tis-
sue concerned or of the amount of plasmid
electrotransfered. Local procedure allows reduced sub-
strate consumption and is more sensitive since it induces
more luminescence. This improved sensitivity after local
injection of luciferin was also shown by Li et al who
detected luciferase activity of transfected rat muscles for a
longer period after local than after i.p. injection of luci-
ferin [31]. Nevertheless intraperitoneal injection of high
amounts of luciferin remains a useful technique when the
site of luciferase production is difficult to reach or is
unknown. In addition, the time to reach peak level of
Reproducibility of in vivo luminescence measurements on muscles after electrotransfer of a luciferase-encoding plasmid Figure 5
Reproducibility of in vivo luminescence measurements on muscles after electrotransfer of a luciferase-encod-
ing plasmid. Values are mean +/- SEM (n = 8 to 10) of the integrated values of luminescence in region of interest (ROI) of the 
tibial cranial muscle 7 days and 8 days after electrotransfer with 0.3 µg (white columns), 3 µg (clear grey columns) and 30 µg 
(dark grey columns) of pC1-luc into the tibial cranial muscle. Individual values are represented by black triangles and lines link 
values for the same muscles at day 7 and 8 after electrotransfer. For each amount of plasmid electrotransferred, luminescence 
values at day 7 (D7) and 8 (D8) did not differ. For both time of measurement (D7 and D8) a significant dose effect was 
observed. *** p < 0.001 between 0.3 and 3 µg (for groups D7 or D8). * p < 0.05 between 3 and 30 µg (for group D7 or D8). 
For all points, background luminescence was subtracted Inset: Linear correlation between values of luminescence measured at 
day 7 and 8 after electrotransfer. R2 = 0.92, p < 0.0001.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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In vivo kinetic of luciferase expression in the knee joint and in the tibial cranial muscle and antibody concentration in blood  serum after electrotransfer of luciferase-encoding plasmid Figure 6
In vivo kinetic of luciferase expression in the knee joint and in the tibial cranial muscle and antibody concentra-
tion in blood serum after electrotransfer of luciferase-encoding plasmid. Panel A: Mean + SEM (n = 8) of the inte-
grated values of luminescence in region of interest (ROI) of the knee joint at different times after electrotransfer of 60 µg/10 µl 
of pC1-luc plasmid (black square symbols) or empty plasmid (black diamond symbols). The in vivo luminescence was assayed 2 
minutes after luciferin injection into the joint. Panel B: Mean ± SEM (n= 6 to 10) of the integrated values of luminescence in 
region of interest (ROI) of the tibial cranial muscle at different times after electrotransfer of 0.3 µg (White columns) or 30 µg 
(grey columns) of pC1 luc plasmid. The in vivo luminescence was assayed 2 minutes after luciferin injection into the electro-
transfered muscle. For all point background luminescence was subtracted. Statistical significance for comparisons of lumines-
cence between different times after electrotransfer of 30 µg of plasmid **** p < 0.0001, ** p < 0.01; after electrotransfer of 0.3 
µg of plasmid $$ p < 0.01 Inset: Mean + SEM (n = 5) of the concentration of antibodies against luciferase in the blood serum at 
different times after electrotransfer of 0.3 µg (empty triangles) or 30 µg (black diamon) of pC1 luc plasmid into the muscle.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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luminescence in one tissue after i.p. luciferin injection is
related to the time for the substrate to access its target. This
might, for example, provide information on blood per-
fusion.
We observed a slower luminescence decrease after local
injection of luciferin in the knee joint than in the muscle.
This decrease of luminescence with time in vivo could be
related to a decrease of substrate concentration because of
diffusion and washout by the circulation. Such an hypoth-
esis is sustained by the stability of luminescence on cells
in vivo [32]. However, we used a large excess of substrate
(100 µg luciferin vs < 100 ng luciferase in the muscle i.e at
minimum 1000 times more substrate), and can assume
that diffusion will have not a great effect. Besides, increas-
ing the substrate concentration did neither modified sig-
nificantly the maximum value of luminescence nor the
kinetic of luminescence decrease, highlighting no effect of
the substrate concentration on the signal. Lastly addition
of luciferin (100 µg/40 µl) to isolated electrotransfered
tibial cranial muscle in a multiwell plate induced the same
type of decreased kinetics, despite a large excess of sub-
strate and the absence of washout problems. These differ-
ences also cannot be due to kinetic of diffusion of the
luciferin inside cells since a similar kinetic profile is
obtained by mixing recombinant luciferase to luciferin in
the buffer used for in vitro measurements. Moreover the
amount of luciferase protein in the cells seemed to remain
constant and the cofactors required for the reaction (ATP,
O2, Mg2+ principally) were in sufficient excess since a new
addition of substrate after return to luminescence back-
ground induced a similar luminescence level in both mus-
cle and knee joint. In conclusion, decrease of
luminescence with time seems essentially related to the
reaction media and/or to enzyme complexation.
Kinetic differences between muscle and knee might thus
be linked to the reaction media which can differ according
to the tissue. For example it has been reported that the
kinetic of light production is related to the concentration
ratio between the enzyme and ATP [33]. The reaction can
also lead to the production of inhibitors of the lumines-
cence [34]. Lastly some molecules present in cells stimu-
late [34,35] and/or inhibit the luminescence [34,36].
As a consequence, luciferase quantification in different tis-
sues is sensitive to the conditions of the reaction. In a
given tissue the quantification will rely on the hypothesis
that these conditions of reaction are the same throughout
the study.
Validation of optical imaging as a tool to quantify 
luciferase activity in vivo
Until now, optical imaging with luciferase was mostly pre-
sented as a semi quantitative technique. From the above
consideration it was thus essential to verify if the values
measured by optical imaging in these experiments were
consistent with values obtained by the classical lumines-
cence quantification method: in vitro measurements on
the supernatant of tissues homogenized in lysis buffer.
We observed a significant correlation between in vivo and
in vitro measurements. This result confirms the results
obtained by Wu et al [22], but with a local injection of
substrate, and thus a more sensitive method, and for a
wide range of plasmid dose. In addition, a clear dose effect
was observed in vivo 8 days after intramuscular electro-
transfer of 0.3, 3 or 30 µg of plasmid, which is consistent
with in vitro measurements of this study and confirmed
the in vitro results of a previous work [37]. Moreover, opti-
cal imaging system was sensitive enough to detect lumi-
nescence resulting from the reaction of luciferase with
luciferin as soon as 6 hours after intramuscular electro-
transfer of 0.3 µg of pCMV-luc+ plasmid. Finally a good
reproducibility of luminescence measurements was
observed at times for which transfection level of the mus-
cle is known to be stable [30].
We can thus assume that variations of luminescence
detected with a cooled CCD camera are sensitive enough,
accurate and well related to the effective amount of luci-
ferase present in the studied tissue.
Taking into account differences between measurement
systems (conversion factor between the two devices, see
Material and Methods), our data highlight that lumines-
cence in vivo was largely lower when compared to that in
vitro. Understanding this discrepancy is necessary to
improve sensitivity of in vivo measurements. One factor
could be the absorption and scattering of light by the tis-
sue. But luminescence attenuation is not sufficient
through a few millimeters of tissue [22,38]. The main
cause of observation of a lower luminescence in vivo must
be linked to the difference in reaction media for in vivo
and in vitro measurements. Indeed media used in vitro are
optimized in order to maximally enhance the lumines-
cence of the luciferase-luciferin reaction. We thus
observed that when luciferase was diluted in Tris buffer
(pH 8) the luminescence produced after addition of the
substrate and ATP was about 2 orders of magnitude lower
than when diluted in lysis buffer (which also contain
Tris). We verified that part of this improvement was due
to the presence of dithiothreitol (DTT) known to avoid
enzyme degradation [35] and to the triton detergent, both
present in the lysis buffer (data not shown). In addition,
in vitro measurements were usually performed in multi-
well white plates, in which the light emission measured
was higher by one order of magnitude than the lumines-
cence level measured in black plates (data not shown), as
expected from previous studies [39]. Taking into accountBMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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these two factors (difference of reaction media and the
type of plates used) seems sufficient to explain the differ-
ence between in vivo and in vitro measurements. Neverthe-
less, only tomographic measurements could be
appropriate to collect the whole luminescence emerging
from the muscle. Indeed, fluorescent tomographic meas-
urements were proven more sensitive than planar meas-
urements [9].
Our results highlight that luminescence quantification in
one tissue is rather accurate and can be related to the effec-
tive amount of luciferase but requires an additional cali-
bration step to put in adequacy in vivo to  in vitro
measurements. In vivo luminescence levels in different tis-
sues are not directly related to their luciferase contents
because of differences in the condition of in vivo enzy-
matic reaction and in tissue absorption depending on the
location of the tissues. Thus absolute quantification in
studies implying several tissues require preliminary cali-
bration for all the tissues involved.
Kinetics of luciferase expression in the muscle and the 
knee
We have studied kinetic profiles of luciferase activity in
the muscle or in the knee joint electrotransfer of a luci-
ferase-encoding plasmid. To our knowledge electrotrans-
fer into the knee joint was only reported for rats in two
studies [28,29] and non-invasive detection of luciferase
activity in the electrotransferred mouse knee joint has
never been done previously.
High and long term (> 2 months) level of luciferase
expression after intramuscular electrotransfer has been
well documented. Here, we confirm by optical imaging
the stability of luciferase expression for at least 62 days in
tibial cranial muscle after electrotransfer of 0.3 or 3 µg of
luciferase-encoding plasmid. In contrast, a decrease of
luciferase activity occurred three weeks after electrotrans-
fer of the higher dose of 30 µg of plasmid, concomitantly
to the production of antibodies against luciferase. Similar
immune responses were also observed by others, after
pC1luc plasmid DNA transfer into the liver of C57Bl6
mouse [40]. After electrotransfer of 60 µg of plasmid into
the mouse knee joint, luciferase activity reached a peak
between 3 to 6 days and returned to the control level two
weeks after electrotransfer. A similar kinetic profile was
also observed by Ohashi et al by in vitro evaluation of the
transgene expression in the synovium [29]. In contrast
Grossin et al observed expression of an electrotransfered
plasmid encoding for GFP for a longer period and local-
ized mainly in the knee patellae [28]. These differences
may be related to the use of different electrotransfer con-
ditions (injection site, electric conditions and electrodes).
In the present study, by using optical imaging, we have
detected the luminescence of the whole knee and it was
not possible to identify the particular type of cells trans-
fected under the specified conditions. Decrease of luci-
ferase activity in this tissue can be partially explained by
synovial cell turnover. Indeed, antibodies against luci-
ferase were detected as soon as 13 days after electrotrans-
fer of a high dose of plasmid. In muscle, the decrease of
luciferase activity and the concomitant antibodies detec-
tion was only observed while injecting a higher dose of
plasmid. These results confirm that a non-self protein
expressed into myofibres seems to be not detected by the
immune system when its concentration is below a thresh-
old value as demonstrated by Miller et al [41]. With higher
dose of electrotransfered plasmid, the observed immune
response can occur via multiple mechanisms [42]. It is
known that electrotransfer enhances the specific immune
response both by increasing transgene expression and by
inducing inflammation [43,44] which is more important
when high amounts of plasmid are injected [45,46] but is
reversed two weeks after electrotransfer. In summary we
observed a specific humoral immune response against
luciferase and probably cytotoxicity against muscular
fibres expressing the luciferase resulting in decrease of the
luciferase activity. These two types of specific immune
reactions have been observed in several studies in DNA
vaccination models (see for example [42]).
Conclusion
In conclusion we have shown here that optical imaging
allows in vivo visualization and quantitative assay of luci-
ferase activity in two different types of tissue in the mouse
model, the muscle and the knee joint, which defines a
smaller and less vascularized compartment. This observa-
tion can be made after i.p. or local injection of the luci-
ferin substrate. We showed that local injection allowed a
more sensitive detection of luciferase activity with lower
substrate consumption. Luminescence observed in such
conditions can be assumed to be independent from
uncontrolled parameters as diffusion of the substrate to
the target cells or circulation washout.
In the field of gene therapy, this detection method could
be useful for promoter efficacy studies and optimization
of gene transfer methods, in muscle, joint or other tissues
accessible to the substrate of luciferase. Alternatively, luci-
ferase can be used as a tracer by its fusion with other trans-
genic proteins of interest that cannot be easily quantified
and localized, or by transfecting cells of interest with a
luciferase encoding plasmid. This might greatly enhance
the scope and further applications of the present study.
However, care must be taken in future studies toward the
development of a possible immune response against the
reporter transgenic protein when high transgene expres-
sion levels are required.BMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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Methods
Animals
In vivo studies were done using 6 to 8 weeks old female
C57Bl/6 or Swiss mice (Charles River, L'Arbresle, France).
Prior to all procedures, the animals were anaesthetised by
intraperitoneal injection of ketamine and xylazine (Bayer
Pharma, Puteaux, France) (100 and 10 mg/kg, respec-
tively). Studies were conducted following the recommen-
dations of the European Convention for the Protection of
Vertebrates Animals used for Experimentation and the
local Ethic Committee on Animal Care and Experimenta-
tion.
Plasmid DNA
Plasmid pC1-luc is an expression vector carrying a modi-
fied cytosolic firefly luciferase gene (luc+) cloned down-
stream of a CMV promoter.
In one experimental series (Figure 4) we used plasmid pXL
3031 (pCMV-luc+) which also carries the modified
cytosolic firefly luciferase gene (luc+) under the control of
a CMV promoter (gift from Aventis Pharma [47]); it leads
to comparable levels of expression of the luciferase.
Plasmid DNA was purified using Endo-free Qiagen Max-
iprep kits (Qiagen, Germany). All dilutions were done in
saline (NaCl 0.9 %).
Injection and electrotransfer of plasmid into the tibial 
cranial muscle and the knee joint
Plasmid DNA (0.3 to 30 µg/30 µl) was injected into the
tibial cranial muscle. Twenty seconds later, 8 square-wave
electric pulses (200 V/cm, 20 ms, 2 Hz) were delivered
through two stainless steel plate electrodes placed each
side of the shaved leg, using an ECM 830 BTX electropul-
sator (Genetronics, San Diego, CA, USA) [26,30].
For electrotransfer of plasmid into the knee joint, 60 µg
(in 10 µl) were injected into the joint by using a hamilton
syringe. Twenty seconds after the injection, 12 electric
pulses of 250 V/cm, 20 ms each at 2 Hz (personal commu-
nication of Florence Apparailly) were applied using a pair
of stainless steel parallel electrodes (1 cm long, 0.3 cm
large, and 4.5 mm apart) placed at each side of the knee
(anterior-posterior direction).
For all experiments electrical contact with the skin was
ensured by application of a conductive gel.
Optical imaging of luminescence
Luciferin diluted in PBS (Promega, Madison WI, USA) was
injected intraperitonealy (i.p., 2.5 mg/250 µl) or locally
into the tibial cranial muscle (100 to 400 µg/40µl) or the
knee joint (50 to 150 µg/10 µl). Optical imaging was per-
formed with a cooled CCD camera (Apogee, Ap47p,
Auburn Calif, USA) placed in a black box and equipped
with a 60 mm lens opening at F 2.8 (Nikon, Japan). Dis-
tance from the lens to the mouse was of 30 cm. Operating
temperature was set at -25°C. Duration of luminescence
acquisition was between 30 s and 240 s and was initiated
2 minutes after injection of the substrate. Quantum effi-
ciency is > 90 % in the λ range of 500 to 680 nm. Lumi-
nescence levels were integrated in region of interest (ROI)
drawn by hand around luminescence zones correspond-
ing to the tibial cranial muscle and/or knee joint area as
estimated from superposed optical image of the mice.
Background luminescence was subtracted according to
values obtained in ROI drawn on a non transfected zone
of the mice (software β Vision+ from Biospace Mesure,
Paris, France). ROI were very similar from one experiment
to the other. When following kinetic of the luciferase-luci-
ferin reaction strictly the same ROI were used for lumines-
cence images taken at different times. In some
experiments, when the luminescence signal reached back-
ground level, mice were euthanazied to remove tibial cra-
nial muscles which were then frozen at -20°C for further
in vitro luciferase assays.
Optical imaging of fluorescence
To asses the localization of injected plasmid into the knee
joint, fluorescent albumin (BSA, Alexa Fluor 594 conju-
gate from Molecular Probe, Oregon, USA) was injected
into this tissue as described in the previous section. Fluo-
rescence was induced with λex of 540 +/- 20 nm and
observed at λem > 630 nm. Lens aperture: F = 11 and
acquisition time: 0.05 sec
Biochemical luciferase activity assays
After sample thawing, each muscle was homogenized in 1
ml of cell culture lysis reagent (Promega, Charbonnière,
France) supplemented with protease inhibitor cocktail
(Boehringer Mannheim, Mannheim, Germany) (one tab-
let for 50 ml). After centrifugation at 12,000 rpm for 10
min at 4°C, the luciferase activity on 10 µl of the superna-
tant was assessed in 96 wells white plate using a Wallac
Victor luminometer (EG&G Wallac, Evry, France), by inte-
gration of the light produced during 1 s, starting after the
addition of 50 µl of luciferase assay substrate (Promega)
to the lysate. Results were given for the whole muscle in
counts per second (cps) for 1 ml of supernatant. It was not
necessary to substract background luminescence, which
was very low (less than 50 cps).
Determination of a conversion factor for comparison of in 
vivo and in vitro measurements of luminescence
Different amounts of luciferase (0.001 to 10 nmoles) in
10 µl were distributed in wells of a black 96 wells plate,
and 50 µl of luciferin solution (Promega, Madison WI,
USA) were then added in each well. Measurements with
the luminometer or the cooled CCD camera were initiatedBMC Biotechnology 2006, 6:16 http://www.biomedcentral.com/1472-6750/6/16
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2 minutes after addition of the substrate. Conversion fac-
tor is the ratio of measured values with both systems at a
given time.
It was not possible to establish directly a calibration curve
in vivo after injection of different amounts of luciferase
into the knee joint or the muscle. Indeed injected luci-
ferase is distributed in the extracellular space and the addi-
tion of luciferin does not induce detectable luminescence
essentially because of the lack of ATP. We verified that
addition of ATP with luciferin allowed to obtain lumines-
cence but it is not obvious that in these conditions the
luminescence measured would be equivalent to that
measured for the same amount of intracellular luciferase.
Titration of antibodies against luciferase in serum
At different times after electrotransfer, blood samples
were collected by retro orbital puncture of anaesthetized
mice, centrifuged at 3000 rpm for 10 minutes at 4°C, and
serums were conserved at -80°C for further ELISA anti-
body detection. Microtiter plates were coated overnight at
room temperature with luciferase (1 µg/ml, Promega,
Madison WI, USA) in 100 µl of PBS. The wells were then
saturated for 30 minute at 37°C with 100 µl of blocking
buffer (PBS/0.1% Tween 20/0.2% gelatine). Serum were
diluted at 1:1000 in 100 µl of blocking buffer and incu-
bated for 1 h at 37°C. Then 100 µl of horseradish peroxi-
dase-conjugated goat anti-mouse secondary antibody
(diluted 1:2000) in wash buffer (PBS/0.1% Tween 20)
was added to the plates and incubated for an additional
hour at 37°C. Bound antibody was detected colorimetri-
cally by using ortho-phenilenediamine (Sigma, USA) as a
substrate, diluted in sodium citrate buffer (0.1 M sodium
citrate plus 0.1 M citric acid, pH 5.0) to a final concentra-
tion of 1 mg/ml. Color was assayed at 492 nm after 5 min
incubation at room temperature. Serum samples from
individual animals were assayed in triplicate. As a control
and for quantification, a serial dilution of a monoclonal
antibody anti-luciferase (Sigma, L2164) was used ranging
from 0 to 2 µg/ml in blocking buffer.
Statistics
Variance analyses on log values of the measured parame-
ters, and a protected least significance test of Fisher for
comparison between treatments have been used. Correla-
tions between groups of paired values were established by
a linear regression analysis. Values of several separate
experiments have been gathered when variance analysis
showed no significant difference between these experi-
ments.
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Appendix
Estimation of luciferase amount in the tibial cranial muscle 
from in vivo luminescence measurement
It is not possible to evaluate exactly the amount of luci-
ferase corresponding to in vivo detected luminescence. But
estimation is possible. Indeed from linear calibration
curve y = Ax + B, we know the relation between lumines-
cence in vitro y and the amount of luciferase x. Next from
experiment in figure 3 we know the mean ratio k between
luminescence measured in vitro y and luminescence in vivo
y' for the same amount of luciferase i.e k = y/y'. It results
that amount of luciferase in vivo x' ≈ (y'.k - B)/A. Hypoth-
esis being that the ratio between luminescence in vitro and
in vivo is constant and not dependant of the amount of
luciferase. Results of figure 3 indicate the level of approx-
imation of such a hypothesis. In addition such a calcula-
tion cannot be extrapolated to other tissues where the
luminescence reaction is different.
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